With a second phase 3 win for Tyvaso in idiopathic pulmonary fibrosis (IPF), United Therapeutics is padding the case for an ...

Promotional materials for a handful of biologics have found their way into the FDA’s hot seat. | Promotional materials for a handful of biologics have found their way into the FDA’s hot seat.

After notching a phase 2 trial win, Idorsia’s insomnia med Quviviq (daridorexant) is one step closer to potentially becoming a first-in-class treatment for children. | After notching a phase 2 trial ...

Takeda has started a workforce reduction in the U.S. as the company aims to save more than 200 billion Japanese yen ($1.26 billion) in annual costs. | Takeda has started a workforce reduction in the U ...

After Spinraza's FDA approval nearly a decade ago, Biogen's spinal muscular atrophy (SMA) drug captured rapid momentum and delivered blockbuster-level sales in just its second year on the market. | ...

High-flying Samsung Biologics is facing a rare bit of public turbulence after the CDMO’s labor union secured the votes needed to strike, signaling a potential escalation in an impasse over what the | ...

Takeda is launching a restructuring, targeting nearly $1.3 billion in annual savings. Generic versions of Novo Nordisk's ...

With an end-of-week green light from the FDA, Rocket Pharmaceuticals has officially broken into commercial orbit.  | Rocket ...

Addressing pressing questions about upcoming ATTR-CM competition and market opportunity, Alnylam management on Tuesday ...

Ionis Pharmaceuticals is dramatically lowering the price of its blockbuster hopeful Tryngolza (olezarsen) as it prepares to ...

There’s no need to dive fast and furious into every single wellness trend, according to a Ludacris-fronted campaign from Bayer’s consumer health division. | There’s no need to dive fast and furious ...

A high-profile drug fraud case that could see the pharmaceutical industry thrown into the Racketeer Influenced and Corrupt ...